Samsung Bioepis and Teva Pharmaceutical Industries have agreed to develop and commercialize two immunology biosimilar candidates, SB41 and SB44, expanding Samsung Bioepis’ development pipeline to nine products from seven. SB41 references AstraZeneca’s Fasenra (benralizumab), while SB44 references Novartis’ Ilaris (canakinumab). Samsung Bioepis will oversee development, regulatory approvals and manufacturing, and Teva will market the products in the United States, Europe and Canada. The companies may extend the arrangement to additional territories and collaborate on further biosimilar development. The deal builds on their work commercializing Epysqli in the United States and Opuviz in Canada.